Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
- PMID: 35093310
- PMCID: PMC8798788
- DOI: 10.1016/j.envres.2022.112816
Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
Abstract
Since the appearance in the late of December 2019, SARS-CoV-2 is rapidly evolving and mutating continuously, giving rise to various variants with variable degrees of infectivity and lethality. The virus that initially appeared in China later mutated several times, wreaking havoc and claiming many lives worldwide amid the ongoing COVID-19 pandemic. After Alpha, Beta, Gamma, and Delta variants, the most recently emerged variant of concern (VOC) is the Omicron (B.1.1.529) that has evolved due to the accumulation of high numbers of mutations especially in the spike protein, raising concerns for its ability to evade from pre-existing immunity acquired through vaccination or natural infection as well as overpowering antibodies-based therapies. Several theories are on the surface to explain how the Omicron has gathered such a high number of mutations within less time. Few of them are higher mutation rates within a subgroup of population and then its introduction to a larger population, long term persistence and evolution of the virus in immune-compromised patients, and epizootic infection in animals from humans, where under different immune pressures the virus mutated and then got reintroduced to humans. Multifaceted approach including rapid diagnosis, genome analysis of emerging variants, ramping up of vaccination drives and receiving booster doses, efficacy testing of vaccines and immunotherapies against newly emerged variants, updating the available vaccines, designing of multivalent vaccines able to generate hybrid immunity, up-gradation of medical facilities and strict implementation of adequate prevention and control measures need to be given high priority to handle the on-going SARS-CoV-2 pandemic successfully.
Keywords: Immune escape; Omicron; Omicron origin; Prevention and control; Vaccine failure; Variant of concern.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures

Similar articles
-
Across-the-board review on Omicron SARS-CoV-2 variant.Inflammopharmacology. 2025 Jan;33(1):1-10. doi: 10.1007/s10787-024-01627-4. Epub 2024 Dec 23. Inflammopharmacology. 2025. PMID: 39714724 Review.
-
Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.J Infect Public Health. 2023 Jan;16(1):4-14. doi: 10.1016/j.jiph.2022.11.024. Epub 2022 Nov 19. J Infect Public Health. 2023. PMID: 36446204 Free PMC article. Review.
-
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633. Elife. 2022. PMID: 36004719 Free PMC article.
-
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.Microbiol Spectr. 2022 Apr 27;10(2):e0273221. doi: 10.1128/spectrum.02732-21. Epub 2022 Mar 30. Microbiol Spectr. 2022. PMID: 35352942 Free PMC article.
-
The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.Front Med (Lausanne). 2022 May 20;9:849217. doi: 10.3389/fmed.2022.849217. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35669924 Free PMC article. Review.
Cited by
-
Proteomic Approach for Comparative Analysis of the Spike Protein of SARS-CoV-2 Omicron (B.1.1.529) Variant and Other Pango Lineages.Proteomes. 2022 Oct 14;10(4):34. doi: 10.3390/proteomes10040034. Proteomes. 2022. PMID: 36278694 Free PMC article.
-
COVID-19 Pharmacotherapy: A Summary of Key Advances and Insights from the Special Issue.Viruses. 2023 Nov 22;15(12):2286. doi: 10.3390/v15122286. Viruses. 2023. PMID: 38140527 Free PMC article.
-
Effectiveness and safety analysis of SanHanHuaShi granules for the treatment of coronavirus disease 2019: Study protocol and statistical analysis plan for a randomized, parallel-controlled, open-label clinical trial.Front Pharmacol. 2022 Aug 16;13:936925. doi: 10.3389/fphar.2022.936925. eCollection 2022. Front Pharmacol. 2022. PMID: 36052134 Free PMC article.
-
Potential protective association of the AA genotype and a allele of CXCR4 rs2228014 polymorphism with COVID-19 severity in adult egyptians.BMC Infect Dis. 2024 Oct 15;24(1):1158. doi: 10.1186/s12879-024-09602-8. BMC Infect Dis. 2024. PMID: 39407172 Free PMC article.
-
Peptidome Surveillance Across Evolving SARS-CoV-2 Lineages Reveals HLA Binding Conservation in Nucleocapsid Among Variants With Most Potential for T-Cell Epitope Loss in Spike.Front Immunol. 2022 Jun 23;13:918928. doi: 10.3389/fimmu.2022.918928. eCollection 2022. Front Immunol. 2022. PMID: 35812370 Free PMC article.
References
-
- Ahmed W., Bivins A., Smith W.J.M., Metcalfe S., Stephens M., Jennison A.V., Moore F.A.J., Bourke J., Schlebusch S., McMahon J., Hewitson G., Nguyen S., Barcelon J., Jackson G., Mueller J.F., Ehret J., Hosegood I., Tian W., Wang H., Yang L., Bertsch P., Tynan J., Thomas K.V., Bibby K., Graber T.E., Ziels R., Simpson S.L. Detection of the Omicron (B.1.1.529) variant of SARS-CoV-2 in aircraft wastewater. Sci. Total Environ. 2022;153171 doi: 10.1016/J.SCITOTENV.2022.153171. - DOI - PMC - PubMed
-
- Ai J., Zhang H., Zhang Yi, Lin K., Zhang Yanliang, Wu J., Wan Y., Huang Y., Song J., Fu Z., Wang H., Guo J., Jiang N., Fan M., Zhou Y., Zhao Y., Zhang Q., Liu Q., Lv J., Li P., Qiu C., Zhang W. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg. Microb. Infect. 2021:1–24. doi: 10.1080/22221751.2021.2022440. - DOI - PMC - PubMed
-
- Aleem A., Akbar Samad A.S., Slenker A.K. 2022. Emerging Variants of SARS-CoV-2 and Novel Therapeutics against Coronavirus (COVID-19) - PubMed.https://www.ncbi.nlm.nih.gov/books/NBK570580/ - PubMed
-
- Andreano E., Paciello I., Piccini G., Manganaro N., Pileri P., Hyseni I., Leonardi M., Pantano E., Abbiento V., Benincasa L., Giglioli G., De Santi C., Fabbiani M., Rancan I., Tumbarello M., Montagnani F., Sala C., Montomoli E., Rappuoli R. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature. 2021 doi: 10.1038/S41586-021-04117-7. - DOI - PMC - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous